REGN5459 Demonstrates Early Promise in Heavily Pretreated Mu

Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.

Related Keywords

Indiana , United States , Indiana University , Bloomington , Attaya Suvannasankha , Department Of Medicine , Bren Simon Comprehensive Cancer Center , Iu Health System , Division Of Hematology Oncology , Indiana University Iu School Of Medicine , Indiana University Melvin And Bren Simon Comprehensive Cancer Center , Immuno Oncology , News , Multiple Myeloma ,